Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed

Insmed Inc. (NASDAQ:INSM) stock surged Thursday following a report that French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is exploring a potential acquisition of the respiratory disease specialist . The potential acquisition comes as Sanofi seeks new growth opportunities to reduce its reliance on blockbuster drug Dupixent. Sanofi Explores Potential Insmed Takeover Bloomberg reported Thursday…

With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed

Sanofi is actively scouting a potential acquisition of Insmed Inc. (NASDAQ:INSM), a respiratory disease specialist, as it seeks new growth avenues to mitigate its dependency on the blockbuster drug Dupixent. Insmed's pipeline includes two commercial respiratory drugs: Brinsupri (brensocatib) and Arikayce (amikacin liposome inhalation suspension).

The former treats non-cystic fibrosis bronchiectasis, while the latter targets refractory Mycobacterium avium complex (MAC) lung disease. In Q3, Brinsupri generated $400.1 million in sales, while Arikayce sales reached $124.4 million. Insmed is projected to achieve Brinsupri revenue of $1.35 billion to $1.4 billion in 2026, and Arikayce sales of $460 million to $470 million.

The French pharmaceutical giant is also evaluating Inmed's treprostinil palmitil inhalation powder (TPIP) for four lung disease indications, as well as INS1148, INS1033, and next-generation DPP1 inhibitors in its early-stage pipeline.

Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at benzinga.com →

More in Finance & Markets

More from Thursday 19 November →